AFP and hepatocellular carcinoma: However, recent studies have found a much lower threshold of annual HCC incidence of 0.4% or greater to be cost-effective for semiannual ultrasound and alpha-fetoprotein surveillance among patients with compensated cirrhosis, likely due to improved survival with recent advances in cirrhosis and HCC management.